| pubmed-article:20840318 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0030193 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0153690 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0217843 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0231220 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0547040 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0205088 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C1328193 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C2713006 | lld:lifeskim |
| pubmed-article:20840318 | lifeskim:mentions | umls-concept:C0908489 | lld:lifeskim |
| pubmed-article:20840318 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:20840318 | pubmed:dateCreated | 2010-9-15 | lld:pubmed |
| pubmed-article:20840318 | pubmed:abstractText | To report the final analysis of a Phase II trial, which investigated the safety and efficacy of the specific endothelin A receptor antagonist zibotentan (AstraZeneca, Macclesfield, UK) in patients with metastatic castration-resistant prostate cancer (CRPC). | lld:pubmed |
| pubmed-article:20840318 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20840318 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20840318 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20840318 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20840318 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20840318 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20840318 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20840318 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20840318 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20840318 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:20840318 | pubmed:issn | 1464-410X | lld:pubmed |
| pubmed-article:20840318 | pubmed:author | pubmed-author:DawsonNancy... | lld:pubmed |
| pubmed-article:20840318 | pubmed:author | pubmed-author:BeuzebocPhili... | lld:pubmed |
| pubmed-article:20840318 | pubmed:author | pubmed-author:BorreMichaelM | lld:pubmed |
| pubmed-article:20840318 | pubmed:author | pubmed-author:CatyArmelleA | lld:pubmed |
| pubmed-article:20840318 | pubmed:author | pubmed-author:ZonnenbergBer... | lld:pubmed |
| pubmed-article:20840318 | pubmed:author | pubmed-author:PayneHeatherH | lld:pubmed |
| pubmed-article:20840318 | pubmed:author | pubmed-author:JamesNicholas... | lld:pubmed |
| pubmed-article:20840318 | pubmed:author | pubmed-author:McIntoshStuar... | lld:pubmed |
| pubmed-article:20840318 | pubmed:author | pubmed-author:MorrisThomasT | lld:pubmed |
| pubmed-article:20840318 | pubmed:author | pubmed-author:PhungDeD | lld:pubmed |
| pubmed-article:20840318 | pubmed:copyrightInfo | © 2010 DRUG SAFETY RESEARCH UNIT. | lld:pubmed |
| pubmed-article:20840318 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20840318 | pubmed:volume | 106 | lld:pubmed |
| pubmed-article:20840318 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20840318 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20840318 | pubmed:pagination | 966-73 | lld:pubmed |
| pubmed-article:20840318 | pubmed:dateRevised | 2011-2-1 | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:meshHeading | pubmed-meshheading:20840318... | lld:pubmed |
| pubmed-article:20840318 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20840318 | pubmed:articleTitle | Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. | lld:pubmed |
| pubmed-article:20840318 | pubmed:affiliation | Division of Cancer Studies, University of Birmingham, Birmingham, UK. n.d.james@bham.ac.uk | lld:pubmed |
| pubmed-article:20840318 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20840318 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:20840318 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:20840318 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:20840318 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20840318 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20840318 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20840318 | lld:pubmed |
